Potential Prion Disease Therapy UncoveredGenetic Engineering NewsTacrolimus is an immune suppressant widely used in organ transplantation. Tacrolimus could prove problematic as an antiprion drug, however, because of issues including possible neurotoxic…
Potential Therapy for Human Prion DiseaseScience Daily (press release)The two compounds are already marketed as the drugs tacrolimus and astemizole. Tacrolimus is an immune suppressant widely used in organ transplantation. Tacrolimus could prove proble…
GSK tries new indication for lupus drug BenlystaWRAL Tech WireGSK is studying the Benlysta/azathioprine combination in patients who have a particular vasculitic disease called ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis. The high …
All glucocorticoids linked to increased risk of VTEThe Oncology ReportSystemic glucocorticoids, including betamethasone, methylprednisolone, prednisolone, prednisone, triamcinolone, and hydrocortisone, raised VTE risk to the highest degree. (No patient…
|
600th Heart Attack Patient Recruited into Phase III CicloMulsion(R) CIRCUS Trial
PharmaLive (press release) (subscription) NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac … |
|
600th Heart Attack Patient Recruited into Phase III CicloMulsion® CIRCUS Trial
PR Newswire UK (press release) NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac … |
|
Breast cancer treatment ‘not value for money’
WebMD.Boots.com 21st March 2013 – Provisional draft guidance by the National Institute for Health and Clinical Excellence (NICE) does not recommend the drug everolimus (Afinitor) as an NHS-funded treatment for HER2 negative, hormone-receptor-positive advanced breast … |
 Telegraph.co.uk |
NICE draft rejects everolimus for advanced breast cancer
OnMedica NICE’s decision today not to recommend everolimus (Afinitor) has met with anger from women with advanced breast cancer who have limited treatment options available. But Breast Cancer Campaign has urged doctors to try to provide it through the Cancer … Breakthrough breast cancer drug ‘too expensive’Telegraph.co.uk Breast cancer treatment ‘not value for money’WebMD.Boots.com NICE issues negative draft decision for Novartis’ AfinitorThe Pharma Letter PMLiVE –Huffington Post UK all 24 news articles » |
|
NICE rejects Novartis’ Afinitor, but OKs GSK’s Revolade, InterMune’s Esbriet
PharmaTimes According to Novartis, Afinitor (everolimus) is the first new licensed therapeutic approach in fifteen years offering substantial impact on hormone responsive advanced breast cancer, which affects over 30,000 women in the UK. The gold standard of care … Positive NICE news for GSK’s Revolade and InterMune’s EsbrietThe Pharma Letter |
Telegraph.co.uk |
Breakthrough breast cancer drug ‘too expensive’
Telegraph.co.uk At that stage, chemotherapy is usually the only option. Last September early trial results were published showing that when combined with chemo, everolimus could more than double the time tumours were ‘stalled’, compared to chemo alone. The respective … Breast cancer drug does not provide value for money, regulator rulesThe Guardian UK cost body rejects Novartis breast cancer drugReuters UK |